Patrick Weldon, MD
Neurology · Jackson, MSNPI 1003907460
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,747 of the $84,525 with a category attached, or 84.9%. Teva Pharmaceuticals USA, Inc. accounts for 89.1% of it on its own, with 32 other manufacturers making up the rest. Among neurology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 505 payments — averaging $167.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$75K
- Corium, LLC$2K
- SK Life Science, Inc.$1K
- Amgen$643
- Lilly USA, LLC$614
- AbbVie$597
- plus $4K from 27 others
What the payments were for
- Consulting fees$2,4553%
- Speaking & faculty fees$71,74785%
- Travel & lodging$8921%
- Food & beverage$9,32511%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 111 | $75,310 |
| Corium, LLC | 7 | $1,901 |
| SK Life Science, Inc. | 51 | $1,132 |
| Amgen | 56 | $643 |
| Lilly USA, LLC | 31 | $614 |
| AbbVie(2 entities) | 22 | $597 |
| Sanofi | 20 | $505 |
| Novartis | 33 | $398 |
| ANI Pharmaceuticals, Inc. | 20 | $382 |
| Sunovion Pharmaceuticals Inc. | 30 | $364 |
| Sumitomo Pharma America, Inc. | 19 | $343 |
| Argenx US, Inc. | 10 | $317 |
| UCB, Inc. | 11 | $246 |
| Eisai Inc. | 12 | $238 |
| Neurocrine Biosciences, Inc. | 11 | $233 |
| Lundbeck LLC | 10 | $215 |
| Biogen | 9 | $207 |
| Pfizer | 11 | $196 |
| EMD Serono, Inc. | 8 | $159 |
| Medtronic | 2 | $119 |
| Impel Pharmaceuticals Inc. | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $36 |
| Livanova USA, Inc. | 1 | $27 |
| Boston Scientific | 1 | $27 |
| Assertio Therapeutics, Inc. | 2 | $26 |
| GE HealthCare | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$39,239
- AUSTEDO$34,402
- ADLARITY$1,750
- BOTOX$138
- UBRELVY$123
- LEMTRADA$123
- VYVGART$119
- PURIFIED CORTROPHIN GEL$105
How this compares
$84,525 in reported general payments places this provider in the 90th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 27 | $239,656 |
| AptiomEslicarbazepine Acetate | 56 | $103,492 |
| BriviactBrivaracetam | 56 | $81,909 |
| QuliptaAtogepant | 60 | $66,254 |
| Nurtec OdtRimegepant Sulfate | 31 | $58,898 |
| XcopriCenobamate | 45 | $51,003 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $34,189 |
| FycompaPerampanel | 21 | $31,226 |
| UbrelvyUbrogepant | 18 | $26,628 |
| Emgality PenGalcanezumab-Gnlm | 12 | $15,254 |
| NayzilamMidazolam | 16 | $10,720 |
| Rasagiline Mesylate | 135 | $10,404 |
| Memantine Hcl | 565 | $5,892 |
| Carbamazepine ErCarbamazepine | 44 | $3,549 |
| Primidone | 178 | $2,621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $75,310 | $239,65627 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $364 | $103,49256 claims |
| AbbVieQulipta, Ubrelvy | $597 | $92,88178 claims |
| UCB, Inc.Briviact, Nayzilam | $246 | $92,62972 claims |
| PfizerNurtec Odt | $196 | $58,89831 claims |
| SK Life Science, Inc.Xcopri | $1,132 | $51,00345 claims |
| Eisai Inc.Fycompa | $238 | $31,22621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 neurology providers in Mississippi.
Other neurology in Jackson
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Rajesh SharmaJackson$152K
- Riichi OtaJackson$53K
- Mitchell MyersJackson$43K
- Tiffany ScarffJackson$29K
- Derek LetortJackson$25K
- Shreyas GangadharaJackson$20K
- Juebin HuangJackson$20K
- David McHenryJackson$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.